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-Type Natriuretic
eptide in Children
tep by Step. . .*
henral Socrates, MD, Nisha Arenja, MD,
hristian Mueller, MD
asel, Switzerland
eonate and pediatric cardiovascular patients present an
xtra challenge to most physicians because of a lack of a
ell-communicated history. Symptoms for this cohort in-
lude dyspnea, failure to thrive, swelling, hypotension, and
o on (1). Rapid evaluation of patients presenting with these
ymptoms is needed so that they receive appropriate treat-
ent and can be referred quickly to a cardiologist if
ecessary. Natriuretic peptides (NPs), such a B-type natri-
retic peptide (BNP), could possibly help this scenario to
uide management quickly and effectively; however, at the
ame time, the utility of NPs in this age group is not
stablished.
The Better Not Pout Children! Study conducted by Law
t al. (1), and in this issue of the Journal, is therefore an
mportant and needed addition to our current knowledge on
he use of BNP as a diagnostic tool in neonate and pediatric
atients presenting with findings that could be attributed to
ignificant cardiovascular disease.
See page 1467
NPs are currently cutting-edge tools used in modern
edical centers as a way to quickly identify heart failure in
dult populations. These endogenous peptides are rapidly
ynthesized and secreted by the right and left cardiac
entricles as the 32-amino acid polypeptide BNP and its
nactive amino terminal NT-proBNP (2). In adults, the
ain catalyst for the release of these peptides is left
entricular end diastolic wall stress and wall stiffness (3).
Studies have demonstrated higher NP levels in healthy
eonates as compared with older age groups. They play an
mportant role in homeostasis during the transition of the
irculation from fetal to maturity. Due to the normal total
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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witzerland. Dr. Mueller has received research support and speakers honoraria from
arious diagnostic companies.ody water increases in newborns, there exists an increase in
ystemic pre-load and afterload in pulmonary arterial circu-
ation compounding with the normal stiff myocardium in
his age group, which leads to a dramatic release of NPs (4).
n addition, the lack of sensitivity to NPs that is seen in
ewborns causes more production and secretion of NPs to
aintain adequate diuresis (1,5).
Law et al. (1) addresses the possibility of using NPs to
iagnose cardiovascular diseases in the age range of neonates
o 19-year-olds. This prospective study from a single pedi-
tric center further divided this group of 102 patients into
eonatal (0 to 7 days, n  42) and older age groups (7
ays to 19 years, n  58). These cases of unknown
ardiovascular pathology were eligible for enrollment upon
equest of an urgent cardiologist consult from a noncardi-
logist when presentation included a symptom of suspect
ardiovascular abnormality. Subjects were enrolled from the
mergency department, inpatient wards, nursery, and inten-
ive care unit. BNP samples were obtained within 24 h of
he consult. Upon examination by a cardiologist, blinded to
NP results, the disease groups were defined as “significant”
hen either function or structure was altered; patients were
urther divided into those with and without an anatomic
efect. Abnormal function included systolic dysfunction
ith shortening fraction 28% or a qualitative decrease,
iastolic dysfunction such as enlarged atria, or heart failure
n the absence of systolic failure. Altered structure included
bnormality in chamber size, myocardial thickness, and
ardiovascular abnormality without an anatomic defect (e.g.,
ulmonary hypertension). Anatomic defects included both
ongenital and acquired, for example, coarctation of the
orta or rheumatic valve disease, respectively. Further inves-
igations of chest X-ray and echocardiogram were per-
ormed and were included in the gold standard diagnosis
1).
Importantly, plasma BNP was higher in the neonatal
roup with or without significant cardiac disease in com-
arison with that of the older age group. Median BNP
or neonates with disease (n  31) was 526 pg/ml (mean
,017  1,128 pg/ml) versus 96 pg/ml (mean 134  130
g/ml, p  0.001) for those without the disease (n  11).
edian BNP for the older age group with disease (n  31)
as 122 pg/ml (mean 824  1,330 pg/ml) versus 22
g/ml (mean 66  96 pg/ml, p  0.001) for those without
he disease (n  27). In cases of cardiovascular disease with
n anatomic defect, the values for BNP increase in both
roups. The area under the receiver-operating characteris-
ics curve for the diagnosis of cardiovascular disease was
.90 in neonates and 0.81 in the older age group. With the
utoff levels suggested in their article (170 pg/ml for
eonates and 41 pg/ml for the older age group), the
ensitivity was 94% and 87%, respectively (1).
When considering application of these data in clinicalractice, it may be important to note 2 methodological
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October 6, 2009:1476–7 BNP in Childrenimitations and 2 relevant differences between children and
dults.
First, this study has an inherent limitation, as it included
atients presenting with a broad range of symptoms and
ndings that could be attributed to significant cardiovascu-
ar disease. This makes the translation of their results to our
nd your clinical practice more difficult than those of studies
hat used a specific symptom like acute dyspnea, which was
one, for example, in the BNP (Breathing Not Properly)
tudy, the PRIDE (ProBNP Investigation of Dyspnea in
he Emergency Department) study, and the BASEL
B-Type Natriuretic Peptide for Acute Shortness of Breath
valuation) study (6–8). Second, as appropriately acknowl-
dged by the authors, this study nicely shows that BNP
evels are closely associated with cardiovascular disease, but
id not evaluate whether the additional use of BNP in-
reases diagnostic accuracy on top of all available informa-
ion in the acute care setting. This step must follow in future
tudies. It is worthwhile to remember that in adults, we have
oth evidence from large observational studies that the
dditional use of BNP increases diagnostic accuracy in the
mergency department, as well as data from 3 large ran-
omized controlled studies that the additional use of NP
mproves patient management, as quantified by time to
ischarge or total cost of treatment (2,9).
Among the important differences between the diagnosis
f heart failure in children and adults, the following 2
actors may be particularly relevant. First, it is worthwhile to
oint out that physical examination in children is often
uch more telling than in adults. For example, the presence
f a cardiac murmur and/or hepatomegaly strongly suggests
ardiovascular disease in children, whereas most clinical
igns in adults are present in 50% of patients with acute
eart failure (10,11). Second, in children, anatomical defects
re common causes of heart failure. Therefore, echocardi-
graphy has a profound role in patient management in the
ajority of patients and has a greater impact on final
iagnosis. These echocardiographic findings can quickly
ead the physician to consult not only a cardiologist, but
ven possibly a surgeon when necessary for treatment. In
dults, imaging is recommended in all patients with heart
ailure, but the immediate consequences on patient man-
gement are much smaller.
BNP assessment is not the final answer in cardiological
iagnosis; this remains true in all age groups. It is not a
tandalone test; further evaluation is in general needed,
K
clthough it has clear value in bringing a front-line physician
o a diagnosis. It is critical to diagnose neonatal and
ediatric patients as quickly as possible; because of lack of a
lear history, the gravity of the situation is not always
easured properly. In this regard, BNP may have a great
uture in children as a possible tool in adding details to the
hole story.
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